

RÃ¼diger Hehlmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3883492/publications.pdf>

Version: 2024-02-01

18
papers

3,397
citations

758635

12
h-index

887659

17
g-index

19
all docs

19
docs citations

19
times ranked

3406
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronicâ€phase CML in clinical practice: 3â€year European SIMPLICITY data. European Journal of Haematology, 2021, 106, 82-89.	1.1	14
2	What is the right dosage of dasatinib for treating chronic myeloid leukaemia?. British Journal of Haematology, 2021, 194, 234-234.	1.2	0
3	CML End Phase and Blast Crisis: Implications and Management. Hematologic Malignancies, 2021, , 179-196.	0.2	0
4	The New ELN Recommendations for Treating CML. Journal of Clinical Medicine, 2020, 9, 3671.	1.0	30
5	Chronic Myeloid Leukemia in 2020. HemaSphere, 2020, 4, e468.	1.2	40
6	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 2020, 34, 2074-2086.	3.3	50
7	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronicâ€phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2019, 94, 46-54.	2.0	32
8	Firstâ€line treatment selection and early monitoring patterns in chronic phaseâ€chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2017, 92, 1214-1223.	2.0	36
9	Prognostic relevance of CCAs/Phâˆ in CML settled. Blood, 2017, 130, 2046-2047.	0.6	2
10	Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 468-479.	1.8	8
11	Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 468-479.	1.8	10
12	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	0.8	67
13	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423.	0.8	271
14	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
15	How I treat CML blast crisis. Blood, 2012, 120, 737-747.	0.6	215
16	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 2011, 118, 6760-6768.	0.6	254
17	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, 115, 1880-1885.	0.6	198
18	Chronic myeloid leukaemia. Lancet, The, 2007, 370, 342-350.	6.3	423